Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease

BACKGROUND AND AIMS: Matrix metalloproteinase-9 [MMP9] is implicated in the pathogenesis of ulcerative colitis [UC] via disruption of intestinal barrier integrity and function. A phase 2/3 combined trial was designed to examine the efficacy, safety, and pharmacokinetics of the anti-MMP9 antibody, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandborn, William J, Bhandari, Bal R, Randall, Charles, Younes, Ziad H, Romanczyk, Tomasz, Xin, Yan, Wendt, Emily, Chai, Hao, McKevitt, Matt, Zhao, Sally, Sundy, John S, Keshav, Satish, Danese, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113706/
https://www.ncbi.nlm.nih.gov/pubmed/29767728
http://dx.doi.org/10.1093/ecco-jcc/jjy049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113706/
https://www.ncbi.nlm.nih.gov/pubmed/29767728
http://dx.doi.org/10.1093/ecco-jcc/jjy049

Ejemplares similares